AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02786719
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cycle 4+6 (given daily for 2 days)
Trial: NCT02786719
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycle 4+6 (given daily for 3 days)
Trial: NCT04688580
Drug: XW10172
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various formulations
Trial: NCT00493246
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen
Trial: NCT00214331
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin 500 mg on day 1 followed by 250 mg on days 2-5
Trial: NCT00214331
Drug: gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a single intravenous dose of gentamicin 1.5mg/kg infused over 60 minutes
Trial: NCT00421538
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily injectable placebo (sterilized NaCL 0.9%) for 6 weeks
Trial: NCT00754013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will start with a dose of 1.25 mg/day (1.25 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) placebo.~All doses will be administered orally.
Trial: NCT02242318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00494624
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01132664
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib (BKM120) is the investigational drug. Burparlisib was supplied as 10 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area. Buparlisib capsules were packaged in high density polyethylene bottles with a plastic child resistant closure.
Trial: NCT01132664
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 twice a day from day 1 to Day 14 of a 21-day cycle.
Trial: NCT01322971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally twice daily for seven days
Trial: NCT00892281
Drug: doxycycline (Oracea®) 40 mg modified release as monotherapy
RxNorm normalized name: doxycycline anhydrous 40 MG [Oracea]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take once daily in the morning
Trial: NCT00892281
Drug: doxycycline (Oracea®) 40 mg modified release as add-on therapy
RxNorm normalized name: doxycycline anhydrous 40 MG [Oracea]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take once daily in the morning
Trial: NCT03716934
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug will be chosen based on the preference of the researcher / responsible physician and current clinical practice guidelines.
Trial: NCT00004224
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03720574
Drug: Matching Placebo BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo tablet each morning and evening for a duration of 48 weeks
Trial: NCT01049412
Drug: LY2605541
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
Trial: NCT04189211
Drug: BAT8001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusions.
Trial: NCT01364324
Drug: standard first line anti-TB drugs
RxNorm normalized name: Standard ANSI First Aid KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will perform pharmacokinetic study in gastrectomy and non-gastrectomy group, to evaluate the effect of gastrectomy on pharmacokinetic profile of first-line anti-TB drugs in patients with TB
Trial: NCT02573935
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: p.o. clarithromycin 500 mg twice daily for 63 days
Trial: NCT02573935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet twice daily for 63 days
Trial: NCT02573935
Drug: VCD induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)
Trial: NCT01655524
Drug: ASSUAGE Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of aminophylline injected intravenously 90 seconds following the radioisotope injection in the setting of regadenoson nuclear stress test of the heart.
Trial: NCT03829358
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented milk containing placebo to be consumed once daily for three weeks.
Trial: NCT00742599
Drug: NPO-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml NPO-11
Trial: NCT00742599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml NPO-11(Placebo)
Trial: NCT02947724
Drug: SURGICEL®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insertion of 4 pieces of SURGICEL® inside the cyst cavity. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
Trial: NCT00692224
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo was packed in similar looking bottles and ad similar taste as zinc gluconate drug
Trial: NCT02164734
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: additional premedication in the endotracheal intubation/INSURE arm
Trial: NCT00365287
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00272506
Drug: inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00272506
Drug: long-acting beta2-agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02464826
Drug: Nailprotex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nailprotex apply to the abnormal nail twice daily
Trial: NCT00682214
Drug: Lactose placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
Trial: NCT02191475
Drug: Haizheng Li Xing ® plus tazocin ®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigecycline (Haizheng Li Xing ®) combined with piperacillin/tazobactam (tazocin ®), with or without antifungal therapy
Trial: NCT01370213
Drug: Preparative Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparative Regimen:~1) fludarabine 40 mg/m\^2 x 4 doses on Days -22 through -19 pretransplant, 2) cyclophosphamide 50 mg/kg x 2 doses on Days -20 and -19 pretransplant, 3) total body irradiation 200 cGy twice a day (BID) (at least 6 hours apart) on Day -18 pretransplant,
Trial: NCT00287300
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02315547
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline \[16\]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
Trial: NCT02508402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two milliliters of normal saline given to placebo group .
Trial: NCT01763918
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT03061838
Drug: MabThera®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg intravenously
Trial: NCT02122718
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03061838
Drug: Ritumax®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg intravenously
Trial: NCT01553747
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets twice daily
Trial: NCT04854252
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TIVA opioid-containing anesthesia: fentanyl in a bolus dose of l3 mcg/kg (corrected weight) TIVA opioid-free anesthesia: dexmedetomidine 1-1.5 mcg/kg (corrected weight) for 40 minutes
Trial: NCT04535752
Drug: ANX009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple ascending dose
Trial: NCT04535752
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple ascending dose
Trial: NCT00472797
Drug: Rebif New Formulation Non Titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human interferon beta 1a - Rebif New Formulation
Trial: NCT00472797
Drug: Rebif New Formulation Titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human interferon beta 1a Rebif New Formulation
Trial: NCT00303667
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously (IV) 50 mg/kg on Day -15
Trial: NCT00303667
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously (IV) 50 mg/kg on Days -16 and -15
Trial: NCT02610920
Drug: Iron tracer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive a 30mg injection of subcutaneous iron sucrose into the breast followed by an axillary ultrasound looking for lymph nodes with enhanced reflexivity.
Trial: NCT02944474
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matching lucerastat capsules
Trial: NCT02521077
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 g ascorbic acid dissolved in 500 ml sterile water.
Trial: NCT02135965
Drug: 100mg of Caffeine
RxNorm normalized name: caffeine 100 MG
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg of caffeine on metabolic rate
Trial: NCT02135965
Drug: 200mg of Caffeine
RxNorm normalized name: caffeine 200 MG
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg of Caffeine on metabolic rate
Trial: NCT02135965
Drug: Albuterol 2mg & Caffeine 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol 2mg and 100mg of Caffeine
Trial: NCT02135965
Drug: Albuterol 2mg and Caffeine 200mg
RxNorm normalized name: albuterol 2 MG
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol 2mg and Caffeine 200mg on metabolic rate
Trial: NCT02135965
Drug: Albuterol 4mg and Caffeine 100mg
RxNorm normalized name: albuterol 4 MG
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol 4mg and Caffeine 100mg on metabolic rate
Trial: NCT02135965
Drug: Albuterol 4mg and Caffeine 200mg
RxNorm normalized name: albuterol 4 MG
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol 4mg and Caffeine 200mg on metabolic rate
Trial: NCT03016338
Drug: TSR-042
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg once intravenously on day 1 of cycle (From cycle 1-4 followed by 1000 mg intravenously every 6 weeks for maximum of 2 yrs)
Trial: NCT03349359
Drug: HIV antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV patients are receiving an antiretroviral therapy according to the physician's discretion and the availability of drugs
Trial: NCT01690975
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - single dose at start of each treatment period
Trial: NCT04206228
Drug: Intravenous iron isomaltoside
RxNorm normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active drug, iron isomaltoside, will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (on-label treatment), over 30 minutes only (1,67 ml/min).
Trial: NCT04206228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be prepared according to the randomisation code, and administered as a single intravenous infusion over 30 minutes only (1,67 ml/min).
Trial: NCT01298778
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
Trial: NCT01037582
Drug: NN9924 (oral)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to receive a single dose of NN9924, at escalating dose levels. Progression to next dose will be based on safety evaluation.
Trial: NCT01037582
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose of placebo as a comparator to NN9924, at all dose levels.
Trial: NCT01037582
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to receive a single dose of placebo.
Trial: NCT01057927
Drug: OC000459
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC000459 capsules 2x100mg BID for 28 days
Trial: NCT01057927
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules to match OC000459 100mg capsules, 2 tablets BID
Trial: NCT00632086
Drug: PA32540
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02562417
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02191007
Drug: Calcipotriol Betamethasone ointment and Urea Cream
RxNorm normalized name: betamethasone Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00052026
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered twice daily for 8 months
Trial: NCT02516423
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV
Trial: NCT02162355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 or 2 matching placebo tablets once daily for 10 days
Trial: NCT03794518
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Beta blockers, ACEI, ARB, and aldosterone )
Trial: NCT02761213
Drug: 2-L PEG/Asc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc) COOLPREP is a proprietary name of 2-L PEG/Asc.
Trial: NCT02062034
Drug: Combined antioxidant therapy
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one Tablet for 24 weeks
Trial: NCT02062034
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of oral placebo with identical appearance, form, size than ubiquinone and antioxidant combined therapy for 24 weeks
Trial: NCT03562481
Drug: 1% Buffered Lidocaine 1:100,000 Epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.
Trial: NCT03562481
Drug: 2% Unbuffered Lidocaine 1:100,000 Epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.
Trial: NCT03407521
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02664441
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly placebo injections
Trial: NCT02171390
Drug: Testosterone 250mg injection
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The testosterone 250mg ester intramuscular injections performed in three weeks
Trial: NCT02171390
Drug: Testosteron 50 mg transdermal gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg testosterone gel implemented on every night
Trial: NCT02336620
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSS 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
Trial: NCT00864617
Drug: ADALAT® CC Extended Release Tablets 60 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under non-fasting conditions
Trial: NCT00128934
Drug: levonorgestrel/ethinyl estradiol
RxNorm normalized name: levonorgestrel/ethinyl estradiol 0.1 mg-20 mcg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02946684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy to recFSH during ovarian stimulation
Trial: NCT02470117
Drug: Alginate-based reflux suppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03380520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV nacl 0.9%
Trial: NCT03694808
Drug: Fluad Vaccine
RxNorm normalized name: Fluad 2024-2025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single adjuvanted dose (AD) intramuscular injection
Trial: NCT03694808
Drug: Fluzone HD Vaccine
RxNorm normalized name: Fluzone 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single high dose (HD) intramuscular injection
Trial: NCT00388895
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00118378
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg per day, increasing to 200 mg per day as clinically indicated
Trial: NCT00419549
Drug: Valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single parenteral administration
Trial: NCT02277704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01197417
Drug: Intravenous Magnesium Sulfate
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg (max 2.4 grams), infused at a concentration of 40 mg/ml (1 ml/kg, max 60 ml), every 8 hours for a total of 6 doses
Trial: NCT02560974
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered orally at 1000 mg/m\^2 BID on Days 1 to 15 of a 3-week cycle, for 8 cycles.
Trial: NCT02516410
Drug: Placebo (matched to ivacaftor)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01252719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo was administered thereafter, for a minimum of 7 days and up to a maximum of 10 days (oritavancin and placebo).
Trial: NCT01328236
Drug: Liposome doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INDUCTION THERAPY: 30 mg/m2, IV (in the vein) on day 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
Trial: NCT01471899
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 tablets every 8 hours for 4 days